Evidence map›Paper›PMID 33925302›Full record

ArticleCancers2021

BLBP Is Both a Marker for Poor Prognosis and a Potential Therapeutic Target in Paediatric Ependymoma.

Durgagauri H Sabnis, Jo-Fen Liu, Lucy Simmonds, Sophie Blackburn, Richard G Grundy, Ian D Kerr, Beth Coyle

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Frontiers in oncology · 2024
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Durgagauri H SabnisChildren's Brain Tumour Research Centre, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham NG7 2RD, UK.
Jo-Fen LiuChildren's Brain Tumour Research Centre, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham NG7 2RD, UK.ORCID 0000-0001-5796-7878
Lucy SimmondsChildren's Brain Tumour Research Centre, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham NG7 2RD, UK.
Sophie BlackburnChildren's Brain Tumour Research Centre, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham NG7 2RD, UK.
Richard G GrundyChildren's Brain Tumour Research Centre, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham NG7 2RD, UK.
Ian D KerrSchool of Life Sciences, QMC, University of Nottingham, Nottingham NG7 2UH, UK.ORCID 0000-0002-7544-8454
Beth CoyleChildren's Brain Tumour Research Centre, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham NG7 2RD, UK.ORCID 0000-0003-2957-1862
University of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paediatric ependymomas are aggressive, treatment-resistant tumours with a tendency towards relapse, consistent with a sub-population of therapy-resistant cancer stem cells. These cells are believed to derive from brain lipid binding protein (BLBP)-expressing radial glia, hence we proposed that BLBP may be a marker for ependymoma therapy resistance. BLBP protein expression correlated with reduced overall survival (OS) in patients from two trials (CNS9204, a chemotherapy-led infant trial-5 y OS 45% vs. 80%,

Indexed as

BLBPbrain tumordocosahexanoic aciddrug resistanceependymomaFABP7invasionPPAR

Identifiers

PMID33925302
PMCPMC8123630
OpenAlexW3157716499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.